Breath Therapeutics Announces Initiation of Global Phase 3 Trials for the Treatment of Bronchiolitis Obliterans Syndrome.
Breath Therapeutics Announces Initiation of Global Phase 3 Trials for the Treatment of Bronchiolitis Obliterans Syndrome.
Explore the latest news and publications, innovation milestones, and drug-device insights from PARI and our pharmaceutical partners leveraging eFlow® Technology.
Recent announcements, achievements, and development milestones from PARI's pharmaceutical partners utilizing eFlow® Technology.
Breath Therapeutics Announces Initiation of Global Phase 3 Trials for the Treatment of Bronchiolitis Obliterans Syndrome.